Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER

201461 citationsJournal Articlehybrid Open Access

Authors

Denise A. Yardley · Sarah Cannon

Debu Tripathy · University of Southern California

Adam Brufsky · UPMC Hillman Cancer Center

Hope S. Rugo · University of California, San Francisco

Peter A. Kaufman · Dartmouth–Hitchcock Medical Center

Musa Mayer

Jay Magidson · Clinical Innovations (United States)

Abstract

Prognostic variables identified by LCM define a HER2-positive MBC patient profile and therapies that may be associated with more favourable long-term outcomes, enabling treatment selection appropriate to the patient's disease characteristics.

Topics & Keywords

HER2/EGFR in Cancer Research Cancer Treatment and Pharmacology Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 110, Issue 11, pp. 2756-2764

DOI: 10.1038/bjc.2014.174

Field-Weighted Citation Impact: 3.44